Advertisement
Advertisement
IPHA
Innate Pharma S.A. ADS
1.54
USDSponsored
+0.03
+1.98%
Nov 10, 15:59 UTC -5
Closed
After-Market
1.49
-0.05
-3.57%
Innate Pharma S.A. ADS (IPHA) Earnings
IPHA Earnings Reports
Positive Surprise Ratio
IPHA beat 0 of 3 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Innate Pharma S.A. ADS earnings per share and revenue
On Nov 05, 2026, IPHA reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.08 USD, resulting in a --% surprise. Revenue reached 300.00 thousand, compared to an expected 2.33 million, with a -87.14% difference. The market reacted with a -1.75% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Innate Pharma S.A. ADS's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Innate Pharma S.A. ADS reported EPS of --, missing estimates by --, and revenue of $300.00K, -87.14% below expectations.
How did the market react to Innate Pharma S.A. ADS's Q3 2026 earnings?
The stock price moved down -1.75%, changed from $1.43 before the earnings release to $1.40 the day after.
When is Innate Pharma S.A. ADS expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Innate Pharma S.A. ADS's next earnings report?
Based on --
analysts, Innate Pharma S.A. ADS is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.